The Food and Drug Administration Sept. 26 finalized guidance updating the cybersecurity information device makers should submit to its Center for Devices and Radiological Health or Center for Biologics Evaluation and Research for premarket review of devices that have cybersecurity considerations. The recommendations are intended to help manufacturers meet their obligations under section 524B of the Federal Food, Drug, and Cosmetic Act, enacted in December 2022 as part of the Consolidated Appropriations Act of 2023, which defines “cyber device” as one that includes a device or software that can connect to the internet and be vulnerable to cybersecurity threats.

Related News Articles

Headline
The Cybersecurity and Infrastructure Security Agency April 17 released guidance to reduce risks associated with a reported breach of Oracle cloud services.…
Headline
The National Counterintelligence and Security Center, the FBI, and the Defense Counterintelligence and Security Center yesterday released guidance on…
AHA Cyber Intel
While the rate of cyberattacks on hospitals has risen dramatically, the severity of the impacts has also grown exponentially. Let’s look at the state of cyber…
Headline
The House Energy and Commerce Oversight and Investigations Subcommittee April 1 discussed cybersecurity threats in legacy medical devices during a hearing. The…
Headline
The Trump Administration March 28 announced that it renewed for one year the public emergency for ongoing malicious cyber-enabled activities against the U.S.…
Headline
The FBI March 26 advised that, after extensive investigation and intelligence review, they have not identified any specific credible threat targeted against…